Measurement of Exhaled Nitric Oxide (NO) and Bronchial Provocation Test With Mannitol as a Predictor of Response to Inhaled Corticosteroids in Chronic Cough
Information source: Centre Hospitalier Universitaire de Saint Etienne
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cough; Bronchial Hyperreactivity
Intervention: bronchial provocation test with mannitol (Procedure)
Phase: N/A
Status: Completed
Sponsored by: Centre Hospitalier Universitaire de Saint Etienne Official(s) and/or principal investigator(s): Frédéric COSTES, MD PhD, Principal Investigator, Affiliation: CHU de Saint-Etienne
Summary
Chronic cough is defined by its persistence beyond 8 weeks. Many conditions can explain the
existence of a bronchial inflammation. In the management of chronic cough, the search for
bronchial hyperreactivity (HRB) is recommended. The treatment relies primarily on the
prescription of inhaled corticosteroids. It has been shown recently that the existence of an
HRB with Methacholine (bronchial provocation test used in routine) does predict the
effectiveness of inhaled corticosteroid treatment in no more than 50% of cases.
It is now possible to assess the bronchial inflammation by rapid, non-invasive and
reproducible tests such that the fraction of exhaled nitric oxide (FeNO) and bronchial
provocation test with mannitol. In a retrospective study, it was shown that an increased
value of FeNO (cut-off > 35 ppb) predicts a positive response to treatment with a
sensitivity of 90% and a specificity of 80%.
Clinical Details
Official title: Measurement of Exhaled NO and Bronchial Provocation Test With Mannitol as a Predictor of Response to Inhaled Corticosteroids in Chronic Cough
Study design: Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Primary outcome: The intensity of coughing on a 10-cm visual scale
Secondary outcome: Sensitivity, specificity, positive predictive value and negative predictive value of the threshold value of 35 ppb FeNo to the clinical response seen as positive if the EVA reduces cough of at least 2 cmSensitivity, specificity, positive predictive value and negative predictive value of response to bronchial provocation test with mannitol on the clinical response seen as positive if the EVA reduces cough of at least 2 cm Correlation between the value of FeNo and dose of mannitol causing a fall of 15% of maximum volume expired second (PD15) Score quality of life of the Leicester Cough Questionnaire
Detailed description:
The purpose of this study is to show that the use of the prospective value of exhaled NO can
predict response to treatment with inhaled corticosteroids in adult with chronic cough. In
addition we will assess the interest of the prognosis of bronchial provocation test with
mannitol in this indication.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Chronic Cough during 2 months
- Social Security regimen affiliated
- Consent form signed
Exclusion Criteria:
- Smoking active
- Treatment with angiotensin converting enzyme inhibitor
- Clinical signs of obvious gastroesophageal reflux
- Clinical rhinosinusitis
- Recent respiratory infection (< 1 month)
- Corticosteroid Treatment(oral or inhaled) within 2 weeks
- VEMS < 1 L or < 80% of the theoretical value
- Existence of an obstructive ventilatory disorder defined as a report (FEV/FVC) < 90%
of the theoretical value
Locations and Contacts
CHU de Saint-Etienne, Saint-Etienne 42055, France
Additional Information
Starting date: November 2008
Last updated: November 23, 2010
|